FDA proposes a risk framework for generative AI medical devices

FDA's device centre published a discussion paper and request for feedback on regulating generative-AI-enabled medical devices, with comments due 19 October 2026. It sorts risk on two axes, from passive information to autonomous action and from minor to severe harm from wrong outputs, and floats benchmark testing plus clinical confirmation before market and periodic benchmarking and clinician review sampling afterwards.